Pacira BioSciences, Inc. SEC filings PCRX
Pacira BioSciences, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Apr 7, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jun 4, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | May 28, 2026 | — |
| DEFA14A | Additional proxy material | May 27, 2026 | — |
| DEFA14A | Additional proxy material | May 26, 2026 | — |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| DEFA14A | Additional proxy material | May 20, 2026 | — |
| DEFA14A | Additional proxy material | May 13, 2026 | — |
| DEFA14A | Additional proxy material | May 12, 2026 | — |
| DEFA14A | Additional proxy material | May 5, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEFA14A | Additional proxy material | Mar 11, 2026 | — |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 10, 2024 |
| DEFA14A | Additional proxy material | Apr 18, 2025 | — |
| DEFA14A | Additional proxy material | Apr 17, 2025 | — |
| DEFA14A | Additional proxy material | Mar 14, 2025 | — |
| DEFA14A | Additional proxy material | Apr 22, 2024 | — |
| DEF 14A | Proxy statement | Apr 22, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Apr 21, 2023 | — |
| DEF 14A | Proxy statement | Apr 21, 2023 | — |
| DEFA14A | Additional proxy material | Apr 22, 2022 | — |
| DEF 14A | Proxy statement | Apr 22, 2022 | Jun 7, 2022 |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 8, 2021 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 8, 2020 |
| DEFA14A | Additional proxy material | Apr 22, 2019 | — |
| DEF 14A | Proxy statement | Apr 22, 2019 | Jun 4, 2019 |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 12, 2018 |
| DEF 14A | Proxy statement | Apr 21, 2017 | Jun 13, 2017 |
| DEF 14A | Proxy statement | Apr 21, 2016 | Jun 14, 2016 |
| DEF 14A | Proxy statement | Apr 21, 2015 | Jun 2, 2015 |
| DEF 14A | Proxy statement | Apr 22, 2014 | Jun 3, 2014 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1396814
- Former names
- Pacira Pharmaceuticals, Inc. (until Apr 9, 2019); PACIRA INC (until Nov 5, 2008); Blue Acquisition Corp (until Apr 16, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.